Results from the first Phase 3 study evaluating  the effect of the fixed-dose combination of tiotropium and olodaterol delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease more

Trial published evaluating the efficacy and safety of nintedanib, an investigational therapy being studied in people with idiopathic pulmonary fibrosis … more

Phase 3 data re linagliptin show reductions compared to placebo in African-American adults with type 2 diabetes … more

Two Phase 3 studies add to the body of evidence supporting the importance of first-line treatment with Gilotrif® (afatinib) in patients whose tumors express the EGFR exon 19 deletion mutation … more

As the benefits and safety of Pradaxa® (dabigatran etexilate mesylate) are once again confirmed, Boehringer Ingelheim continues to look for new ways for Pradaxa to help more patients … more


5/22 4:30 pm – 7:30 pm in Hartford
‘Finding Your Path to Funding in Connecticut’s New Entrepreneurial Ecosystem’ … more

6/16 4:30 pm – 6:00 pm in Farmington
BioScienceClubhouseCT presents ‘CORNOVUS Pharmaceuticals: Novel Treatment for Heart Failure’ … more